To Anticoagulate or Not? That Is the Question. Management of High-Risk Patients with Mechanical Mitral and Double Valves: A Case Series
DOI:
https://doi.org/10.1532/hsf.2014Keywords:
anticoagulation, mechanical prosthetic valve, aortic valve replacement, mitral valve replacementAbstract
The Achilles heel of mechanical valves appears to be the need for anticoagulation. Several different types of mechanical valves have come and gone. The success or lack thereof of these valves depended on their various designs. We compared the two most promising mechanical valves of different eras and the need for anticoagulation through a case review. Both the Medtronic-Hall tilting disc valve and the bileaflet On-X valve were compared and contrasted in terms of durability and management of anticoagulation in high-risk patient populations. We present two cases of challenging anticoagulation management: a patient who underwent a mitral valve replacement with a Medtronic-Hall tilting disc valve who was off anticoagulation for close to six years, and a patient who underwent On-X mitral and aortic valve replacements and suffered a subsequent intracranial bleed requiring surgical intervention. We explore the ethical dilemmas associated with these patients and the risk of restarting anticoagulation for each.
References
Antunes MJ, Wessels A, Sadowski RG, et al. 1988. Medtronic-Hall valve replacement in a third-world population group: a review of the performance of 1000 prostheses. J Thorac Cardiovasc Surg 95:980-93.
Antunes MJ. 2015. Requiem for a good mechanical heart valve: Farewell to the Medtronic Hall valve. J Thorac Cardiovasc Surg 149:1492-4.
Butchart EG, Lewis PA, Grunkemeier GL, Kulatilake N, Breckenridge IM. 1988. Low risk of thrombosis and serious embolic events despite low intensity anticoagulation: experience with 1,004 Medtronic-Hall valves. Circulation 78:66-77.
Butchart EG, Hui-Hua L, Payne N, Buchan K, Grunkemeier GL. 2001. Twenty years' experience with Medtronic Hall valve. J Thorac Cardiovasc Surg 121:1090-1100.
Chambers J, Roxburgh J, Blauth C, O’Riordan J, Hodson F, Rimington H. 2005. A randomized comparison of the MCRI On-X and CarboMedics Top Hat bileaflet mechanical replacement aortic valves: Early postoperative hemodynamic function and clinical events. J Thorac Cardiovasc Surg 130:759-64.
Chan V, Jamieson WR, Lam BK, et al. 2010. Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study. J Thorac Cardiovasc Surg 140:1053-8.e2.
ElBardissi AW, DiBardino DJ, Chen FY, et al. 2010. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg 139:1137-45.
Ely JL, Emken MR, Accuntius JA, et al. 1998. Pure pyrolytic carbon: Preparation and properties of a new material, On-X carbon for mechanical heart valve prostheses. J Heart Valve Dis 7:626-32.
Emery RW, Emery AM, Raikar GV, Shake JG. 2008. Anticoagulation for mechanical heart valves: a role for patient based therapy. J Thromb Thrombolysis 25:18-25.
Hansson NC, Grove EL, Andersen HR, et al. 2016. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol 68:2059-69.
Karkar AM, Castresana MR, Odo N, Agarwal S. 2015. Anticoagulation dilemma in a high-risk patient with On-X valves. Ann Card Anaesth 18:257-60.
Kinsley RH, Colsen PR, Antunes MJ. 1983. Medtronic-Hall valve replacement in a Third World population group. Thorac Cardiovasc Surg 31:69-72.
Makkar RR, Fontana G, Jilaihawi, H, et al. 2015. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373:2015-24.
Mostafa EA, El Midany AA, Taha AS, et al. 2018. On-X versus St Jude Medical mechanical prosthesis, in mitral position: are we moving forward in design technology? J Cardiovasc Surg (Torino) 59:252-8.
Nishimura RA, Otto CM, Bonow RO, et al. 2017. AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70:252-89.
Nitter-Hauge S, Enge I, SembBK, Hall KV. 1979. Primary clinical experience with the Hall-Kaster valve in the aortic position: results at 3 months including hemodynamic studies. Circulation 60:55-62.
Puskas J, Gerdisch M, Nichols D, et al. 2014. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 147:1202-10.
Sundt TM, Zehr KM, Dearani JA, et al. 2005. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg 129: 1024-31.
Svennevig JL, Abdelnoor M, Nitter-Hauge S. 2007. Twenty-five–year experience with the Medtronic-Hall valve prosthesis in the aortic position. A follow-up cohort study of 816 consecutive patients. Circulation 116:1785-1800.
Vahanian A, Alfieri O, Andreotti F, et al. 2012. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 42: S1-S44.
Walther T, Falk V, Tigges R, et al. 2000. Comparison of On-X and SJM HP bileaflet aortic valves. J Heart Valve Dis 9:403-7.
Williams MA, Crause L, Van Riet S. 2004. A comparison of mechanical valve performance in a poorly anticoagulated community. J Card Surg 19:410-4.
Williams MA, van Riet S. 2006. The On-X heart valve: mid-term results in a poorly anticoagulated population. J Heart Valve Dis 15:80-6.
Xu Z, Wang ZP, Ou JS, Yin SL, et al. 2016. Is low anticoagulation intensity more beneficial for patients with bileaflet mechanical mitral valves? A meta-analysis. J Cardiovasc Surg (Torino). 57:90-9.
